reports
Integra LifeSciences to Spotlight CereLink® Intracranial Pressure (ICP...
Integra LifeSciences to Spotlight CereLink® Intracranial Pressure (ICP) Monitoring System at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting Visit the Codman Specialty Surgical booth to learn how the CereLink ICP Monitoring System provides patients with uncompromised advanced continuous ICP monitoring. PRINCETON, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, is pleased to announce that following a successful Q1 2024 U.S. relaunch of its , the innovative product will be featured at the upcoming AA...
Merit Medical Reports Results for First Quarter Ended March 31, 2024
Merit Medical Reports Results for First Quarter Ended March 31, 2024 Q1 2024 reported revenue of $323.5 million, up 8.7% compared to Q1 2023Q1 2024 constant currency revenue* up 9.3% compared to Q1 2023Q1 2024 constant currency revenue, organic* up 7.0% compared to Q1 2023Q1 2024 GAAP operating margin of 11.1%, compared to 8.9% in Q1 2023Q1 2024 non-GAAP operating margin* of 17.3%, compared to 16.1% in Q1 2023Q1 2024 GAAP EPS $0.48, up 35.5%, compared to $0.36 in Q1 2023Q1 2024 non-GAAP EPS* $0.77, up 18.7%, compared to $0.64 in Q1 2023 * Constant currency revenue; constant currency revenu...
Stryker reports first quarter 2024 operating results
Stryker reports first quarter 2024 operating results Portage, Michigan, April 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2024: First Quarter Results Reported net sales increased 9.7% to $5.2 billionOrganic net sales increased 10.0%Reported operating income margin of 18.5%Adjusted operating income margin(1) increased 80 bps to 21.9%Reported EPS increased 33.1% to $2.05Adjusted EPS(1) increased 16.8% to $2.50 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquis...
LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more than 20 years in research and development (R&D) to establish an integrated innovation function at LivaNova that will accelerate the Company’s development of new technologies. In this capacity, Tezel will join the LivaNova Executive Leadership Team. “I am very pleased to welcome Ahmet to the LivaNova team. At...
Intuitive Announces Board of Directors Elections and Retirements
Intuitive Announces Board of Directors Elections and Retirements Lewis Chew elected to Intuitive’s BoardAlan Levy, PhD and Don Kania, PhD to retire from Board SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that Lewis Chew, former chief financial officer at Dolby Labs, Inc., has been elected to the Company’s Board of Directors, effective April 25. “Lewis brings decades of experience across global organizations, technologies, and complex suppl...
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incide...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that its wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a cybersecurity incident that was initially disclosed by the Company on November 20, 2023. The incident resulted in a disruption to portions of the Company’s information technology systems. Promptly after detecting the issue on November 19, 2023, LivaNova began an investigation with assistance from external cybersecurity experts and coordinated with law enforcement. The Com...
Integra LifeSciences to Reschedule the First Quarter 2024 Financial Re...
Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024 PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, today announced that it has rescheduled the release of the Company’s first quarter 2024 financial results to Monday, May 6, 2024. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. EDT. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the ...
Intuitive Announces First Quarter Earnings
Intuitive Announces First Quarter Earnings SUNNYVALE, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2024. Q1 Highlights Worldwide da Vinci procedures grew approximately 16% compared with the first quarter of 2023.The Company placed 313 da Vinci surgical systems, compared with 312 in the first quarter of 2023.The Company grew its da Vinci surgical system installed base to 8,887 systems a...
Edwards Lifesciences to Host Earnings Conference Call on April 25, 202...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at . About Edwards Lifesciences Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart d...
Integra LifeSciences Completes the Acquisition of Acclarent, Inc.
Integra LifeSciences Completes the Acquisition of Acclarent, Inc. PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of , a pioneer in ear, nose and throat (ENT) surgical interventions. The addition of Acclarent's innovative product portfolio expands the breadth of Integra’s market-leading brands and provides immediate scale and accretive growth via a dedicated sales channel. The acquisition adds $1 billion to the total addressable market of the Company’s offerings, ...
Stryker to announce financial results for its first quarter of fiscal ...
Stryker to announce financial results for its first quarter of fiscal year 2024 Portage, Michigan, April 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for first quarter of fiscal year 2024 on Tuesday, April 30, 2024. A press release will be issued at approximately 4:05pm ET and available at that day. The press release will include summary financial information for the company’s first quarter of fiscal year 2024, that ended March 31, 2024. Stryker will host a webcast at 4:30pm ET on Tuesday, April 30, to discuss results for its first quar...
Stryker announces Annual Meeting of Shareholders
Stryker announces Annual Meeting of Shareholders Portage, Michigan, March 26, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2024 Annual Meeting of Shareholders is scheduled as follows: Thursday, May 9, 2024 – 9:30 a.m. Eastern Time The Meeting will be held virtually via the internet. Information about the webcast, which will include both the audio and the slide presentation from the meeting, is available on the Investor Relations page of our website at To listen to the meeting as a guest dial (877) 328-2502 (U.S.) or (412) 317-5419 (International) and request the "Stryker...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
XBIT XBIOTECH
UFPT UFP TECHNOLOGIES
TRIP TRIPADVISOR INC.
TPH TRI POINTE HOMES INC.
PSX PHILLIPS 66
MTRX MATRIX SERVICE COMPANY
MSA MSA SAFETY INC.
MRK MERCK & CO. INC.
ISRG INTUITIVE SURGICAL INC.
HUBB HUBBELL INCORPORATED CLASS B
GPK GRAPHIC PACKAGING HOLDING COMPANY
FRPT FRESHPET INC
FANG DIAMONDBACK ENERGY INC.
DY DYCOM INDUSTRIES INC.
COLL COLLEGIUM PHARMACEUTICAL INC.
AL AIR LEASE CORPORATION CLASS A
ALV ALLIANZ SE
GBL GAMCO INVESTORS
CW CURTISS-WRIGHT CORPORATION
MPC. MADISON PACIFIC PROPERTIES INC. CL B
ELY CALLAWAY GOLF COMPANY
TG TREDEGAR CORP.
TAYD TAYLOR DEVICES INC.
HWKN HAWKINS INC.
FSTR L.B. FOSTER CO.
TEC TECHNIPFMC PLC
STRA STRATEGIC EDUCATION INC.
MRVI MARAVAI LIFESCIENCES HOLDINGS
SMLP SUMMIT MIDSTREAM PARTNERS
SGC ONTO INNOVATION INC.
SG CAPITAL PUBLIC COMPANY LIMITED
LivaNova to Announce First-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2024 results prior to the call. A live audiocast will be accessible at . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial (if dialing from within the U.S.) or (if dialing from outside the U.S.). The...
Phillips 66: 1 director
A director at Phillips 66 sold/sold after exercising options 13,122 shares at 157.312USD and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...
LivaNova Announces a Positive Predictive Outcome of Trial Success in i...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its , has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated. This means there is a greater than 97.5% probability that the OSPREY trial will successfully meet its primary endpoint. OSPREY is a prospective, multi-center, randomized controlled open-label trial demonstrating the safety and effectiveness of the aura6000™ Hypoglossal Nerve Stimulator System versus a no stimulation control in subjects with moderate to severe obstructive sleep ...
Boston Scientific Corp: 1 director
A director at Boston Scientific Corp sold 14,506 shares at 66.450USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.